Aestis’ technology induces weight loss without side effects through natural appetite suppression.
More than fifty studies document weight loss from hypoxia – the basis of Aestis technology.
A study recently completed using Aestis’ technology demonstrated weight loss without side effects, or the need for dieting or exercise.
Aestis has assembled a team of experienced managers and expert advisors to guide the company’s commercialization of the technology.
Aestis is raising $1.25 million to complete a preclinical trial as part of its strategy for FDA approval and medical CE marking. Qualified investors are invited to review the company’s business plan.